Key Highlights. 1  In the first full year of IMBRUVICA® (ibrutinib) sales, the Company recorded total revenue of $730 million, driven by U.S. net product revenue of $492 million for the year ended December 31, 2014, compared to U.S. net product revenue of $14 million for the prior year.